Suzhou Basecare Medical (HKSE:02170) PB Ratio: 0.37 (As of Aug. 08, 2026) — 33% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02170 Suzhou Basecare Medical Corp Ltd HKSE:02170
70 GF Score
Price HK$1.40
GF Value HK$2.94
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Suzhou Basecare Medical PB Ratio?

Suzhou Basecare Medical HKSE:02170 70 PB Ratio is 0.37 as of Aug. 08, 2026, which is 33% below its 10-year median of 0.55. GuruFocus rates HKSE:02170 with a GF Score™ of 70/100 and a GF Value™ of HK$2.94 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Suzhou Basecare Medical ranks better than 95.29% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-08), Suzhou Basecare Medical's share price is HK$1.40. Suzhou Basecare Medical's Book Value per Share for the quarter that ended in Dec. 2025 was HK$3.78. Hence, Suzhou Basecare Medical's PB Ratio of today is 0.37.

Good Sign:

Suzhou Basecare Medical Corp Ltd stock PB Ratio (=0.37) is close to 1-year low of 0.34.

The historical rank and industry rank for Suzhou Basecare Medical's PB Ratio or its related term are showing as below:

HKSE:02170' s PB Ratio Range Over the Past 10 Years
Min: 0.23   Med: 0.55   Max: 26.54
Current: 0.37

During the past 8 years, Suzhou Basecare Medical's highest PB Ratio was 26.54. The lowest was 0.23. And the median was 0.55.

HKSE:02170's PB Ratio is ranked better than
95.29% of 786 companies
in the Medical Devices & Instruments industry
Industry Median: 2.115 vs HKSE:02170: 0.37

During the past 12 months, Suzhou Basecare Medical's average Book Value Per Share Growth Rate was -15.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -16.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 11.30% per year.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Suzhou Basecare Medical was 64.80% per year. The lowest was -16.60% per year. And the median was -16.60% per year.

Back to Basics: PB Ratio


Suzhou Basecare Medical  (HKSE:02170) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Suzhou Basecare Medical PB Ratio Related Terms


Suzhou Basecare Medical PB Ratio Historical Data

* Premium members only.

The historical data trend for Suzhou Basecare Medical's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Basecare Medical PB Ratio Chart

Suzhou Basecare Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial 0.87 0.57 0.42 0.61 0.49

Suzhou Basecare Medical Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.38 0.61 0.69 0.49

HKSE:02170 vs ABT, SYK, MDT: PB Ratio Comparison

For the Medical Devices subindustry, Suzhou Basecare Medical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Basecare Medical PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Suzhou Basecare Medical's PB Ratio distribution charts can be found below:

* The bar in red indicates where Suzhou Basecare Medical's PB Ratio falls into.


HKSE:02170
70GF Score
Suzhou Basecare Medical Corp Ltd HKSE:02170
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suzhou Basecare Medical PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Suzhou Basecare Medical's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=1.40/3.775
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 0.37 mean?
Suzhou Basecare Medical (HKSE:02170) has a PB Ratio of 0.37 as of Aug. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Suzhou Basecare Medical and its competitors. This is 33% below median its historical median of 0.55. Over the past decade, Suzhou Basecare Medical's PB Ratio has ranged from 0.23 to 26.54. According to the industry distribution chart, Suzhou Basecare Medical ranks #37 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 4.7%.
Is Suzhou Basecare Medical's PB Ratio too high?
Suzhou Basecare Medical's current PB Ratio of 0.37 is 33% below median its 10-year median of 0.55. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 26.54. The Medical Devices & Instruments industry median PB Ratio is 2.12. Suzhou Basecare Medical's value of 0.37 is 82.5% below this industry median. Based on the distribution chart, Suzhou Basecare Medical ranks #37 out of 786 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Suzhou Basecare Medical has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Suzhou Basecare Medical's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Suzhou Basecare Medical ranks #37 out of 786 companies for PB Ratio. This places Suzhou Basecare Medical in the top 5% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.12. Suzhou Basecare Medical's value of 0.37 is 82.5% below this benchmark. Historically, Suzhou Basecare Medical's own PB Ratio has ranged from 0.23 to 26.54 over the past decade. While the company's 10-year median is 0.55 vs. the industry median of 2.12, Suzhou Basecare Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.12, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Basecare Medical's current PB Ratio of 0.37 is 82.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Suzhou Basecare Medical and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Basecare Medical's current PB Ratio is 0.37, which is 33% below median its own 10-year median of 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Basecare Medical stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Basecare Medical (HKSE:02170) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.94, compared to a current price of HK$1.40 — trading 52.4% below its estimated fair value. The current PB Ratio is 0.37, which is 33% below median its 10-year median of 0.55 and 82.5% below the Medical Devices & Instruments industry median of 2.12. Suzhou Basecare Medical's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Suzhou Basecare Medical (HKSE:02170), the current PB Ratio is 0.37 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Suzhou Basecare Medical (HKSE:02170) Overvalued in 2026?

Based on GuruFocus' analysis, Suzhou Basecare Medical stock appears to be undervalued. The current stock price of HK$1.40 is trading 52.4% below its estimated GF Value™ of HK$2.94. GuruFocus considers Suzhou Basecare Medical to be Possible Value Trap.

Key valuation signals for HKSE:02170:

  • PB Ratio: 0.37 (33% below median its 10-year median of 0.55)
  • GF Value™: HK$2.94 vs. price of HK$1.40 (52.4% below fair value)
  • GF Score™: 70/100 with 7 warning signs
  • Industry Position: 82.5% below the Medical Devices & Instruments median (#37 of 786)

No single metric tells the full story. See the HKSE:02170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Suzhou Basecare Medical Business Description

Address No. 77 Jingu Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Suzhou Basecare Medical Corp Ltd is a medical device company based in China, operating in the field of assisted reproduction. It is engaged in the research, development, and provision of medical products and related software in the field of reproductive health, to enable more families to have children. The Group's product portfolio comprises Gems Sperm Wash Gradient Set, Gems Fertilisation Medium, Gavi Instrument, Geri Incubator, Cryostorage System, PGT-A kit, Self sperm testing device, Sperm quality analyser, Genie sequencer, and others. It generates maximum revenue from the sale of testing kits. The Group's reportable segments are: the PRC, which derives maximum revenue, and Australia. Geographically, it operates in the PRC, Europe, Asia (excluding the PRC), and other regions.
70GF Score

Get the complete analysis for HKSE:02170

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.40
Price
HK$2.94
GF Value